EUVIMEDEUVIMED entdecken
Open Access

Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: HTR3A , HTR3B , TACR1

Winnie Yeo iD, Frankie K F Mo, JingHan Huang iD, Horatio L Yeo, Wan-Hei Ko, Leung V Li, Thomas K H Lau, Kwai T Lai, Elizabeth Pang, Menglin Ou, Suk-Ling Ma iD, Nelson L S Tang iD

JCO Precision Oncology · 2025-04 · (9)

DOI: 10.1200/po-24-00858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-04. Verfasst von Winnie Yeo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, The State Key Laboratory of Translation Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese Univers…. Hauptthemen laut MEDLINE: Antiemetics, Vomiting, Nausea, Receptors, Serotonin, 5-HT3. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Contemporary prophylactic antiemetic regimens have improved the control of chemotherapy-induced nausea and vomiting (CINV). However, over 50% of patients still suffer from nausea. This study aimed to correlate the genetic determinants of individual patients with the efficacy of three prophylactic antiemetic regimens. METHODS Patients with breast cancer in two previously reported prospective antiemetic studies consented for the present pharmacogenetic study. Before high-emetogenic doxorubicin and cyclophosphamide (AC) (neo)adjuvant chemotherapy, they received a combination of antiemetic prophylaxis: regimen A and regimen B were, respectively, aprepitant/ondansetron/dexamethasone with or without olanzapine; regimen C was netupitant/palonosetron/dexamethasone. The effectiveness of antiemetic regimens was mainly assessed by complete protection (CP) rates. Patients' genotypes in three genes, HTR3A , HTR3B and TACR1 , were analyzed. RESULTS Patients who were homozygous TT (p.129Tyr) of a non-nonsynonymous variant in HTR3B rs1176744 and homozygous GG of TACR1 rs3821313 had better outcome with regimen B. Digenic interaction analysis further reveals interaction between rs1176744 and rs3821313. Homozygotes TT of rs1176744 and homozygotes GG of rs3821313 achieved the highest CP rate with regimen B (10/12 patients; 83%), in contrast to only 29% (7/24) with regimen A ( P = .0027). Homozygotes GG in both HTR3A rs1176722 and TACR1 rs3821313 showed the poorest response to regimen A with a CP rate of 17% (2/12), whereas patients given regimen B had the highest CP rate (70%; 7/10; P = .0159). The findings were confirmed upon logistic regression adjusted for clinical factors. CONCLUSION The present study confirmed our hypothesis that among Chinese patients with breast cancer who received AC, the selection of optimal antiemetic prophylaxis may be aided by assessing an individual's pharmacogenetic profile. It also highlights a novel digenic interaction that has not been known before for pharmacogenetic analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsVomitingNauseaReceptors, Serotonin, 5-HT3Receptors, Neurokinin-1Minor Histocompatibility AntigensAntineoplastic AgentsHumansFemaleMiddle AgedBreast NeoplasmsAdultPharmacogenomic TestingProspective StudiesDexamethasoneCyclophosphamidePrecision MedicineAgedAprepitantPalonosetronPharmacogeneticsTacrolimus Binding ProteinsTacrolimus Binding Protein 5

Substanzen

AntiemeticsReceptors, Serotonin, 5-HT3Receptors, Neurokinin-1Minor Histocompatibility AntigensDexamethasoneCyclophosphamideAntineoplastic AgentsAprepitantPalonosetronTacrolimus Binding Proteins

Autor:innen und Institutionen

  • Department of Clinical Oncology, The State Key Laboratory of Translation Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Li Ka Shing Institute of Health Sciences and CAS Center for Excellence in Animal Evolution and Genetics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Winnie Yeo, JingHan Huang, Suk-Ling Ma, Nelson L S Tang

Zitieren

APA

Yeo, W., Mo, F. K. F., Huang, J., Yeo, H. L., Ko, W. H., Li, L. V., Lau, T. K. H., Lai, K. T., Pang, E., Ou, M., Ma, S. L., & Tang, N. L. S. (2025). Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: HTR3A , HTR3B , TACR1. JCO Precision Oncology. https://doi.org/10.1200/po-24-00858

Vancouver

Yeo W, Mo FKF, Huang J, Yeo HL, Ko WH, Li LV, et al. Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: HTR3A , HTR3B , TACR1. JCO Precision Oncology. 2025. doi:10.1200/po-24-00858

BibTeX
@article{Yeo2025,
  author = {Yeo, Winnie and Mo, Frankie K F and Huang, JingHan and Yeo, Horatio L and Ko, Wan-Hei and Li, Leung V and Lau, Thomas K H and Lai, Kwai T and Pang, Elizabeth and Ou, Menglin and Ma, Suk-Ling and Tang, Nelson L S},
  title = {Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: HTR3A , HTR3B , TACR1},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-24-00858}
}
Kostenlos starten →